| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
|
N Engl J Med
|
2004
|
18.93
|
|
2
|
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
|
J Clin Oncol
|
2000
|
16.83
|
|
3
|
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
|
J Clin Oncol
|
2007
|
7.73
|
|
4
|
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
|
N Engl J Med
|
1991
|
7.21
|
|
5
|
Capecitabine as adjuvant treatment for stage III colon cancer.
|
N Engl J Med
|
2005
|
6.22
|
|
6
|
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
|
J Clin Oncol
|
2000
|
5.20
|
|
7
|
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
|
J Natl Cancer Inst
|
2000
|
3.27
|
|
8
|
Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group.
|
N Engl J Med
|
1985
|
3.03
|
|
9
|
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
|
J Clin Oncol
|
2007
|
2.08
|
|
10
|
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
|
Br J Cancer
|
2004
|
2.01
|
|
11
|
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.
|
Ann Oncol
|
2005
|
1.95
|
|
12
|
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
|
Br J Cancer
|
2004
|
1.94
|
|
13
|
X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.
|
Clin Cancer Res
|
1999
|
1.81
|
|
14
|
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
|
J Clin Oncol
|
2007
|
1.79
|
|
15
|
Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer.
|
J Clin Oncol
|
2003
|
1.67
|
|
16
|
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
|
J Clin Oncol
|
2002
|
1.54
|
|
17
|
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
|
Br J Surg
|
1997
|
1.38
|
|
18
|
Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study.
|
Ann Oncol
|
2005
|
1.37
|
|
19
|
Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.22
|
|
20
|
Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation.
|
Pharmacogenomics
|
2006
|
1.14
|
|
21
|
Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule.
|
Int J Radiat Oncol Biol Phys
|
2002
|
1.08
|
|
22
|
High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection.
|
Strahlenther Onkol
|
2002
|
1.06
|
|
23
|
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
|
Br J Cancer
|
2004
|
0.93
|
|
24
|
A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer.
|
Ann Oncol
|
2005
|
0.92
|
|
25
|
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.86
|
|
26
|
Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.85
|
|
27
|
A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.82
|
|
28
|
Adjuvant chemotherapy with oxaliplatin, in combination with fluorouracil plus leucovorin prolongs disease-free survival, but causes more adverse events in people with stage II or III colon cancer Abstracted from: Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
|
Cancer Treat Rev
|
2004
|
0.81
|
|
29
|
Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial.
|
Oncotarget
|
2016
|
0.75
|